Literature DB >> 15099962

Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy.

Chih-Ming Ho1, Tsai-Yen Chien, Shih-Hung Huang, Ching-Jung Wu, Bor-Yuan Shih, Shang-Che Chang.   

Abstract

OBJECTIVE: This study was performed to identify pathologic and clinical risk factors that best predicted 5-year recurrence-free survival (RFS) among patients with early-stage cervical carcinoma, treated by radical hysterectomy and pelvic lymphadenectomy.
METHODS: The records of 197 patients with early-stage invasive cervical carcinoma who underwent radical hysterectomy and pelvic lymphadenectomy from 1990 to 1999 were retrospectively reviewed. Clinical and pathologic variables including age, tumor size (TS), clinical stage, depth of invasion (DI), lymphovascular space involvement (LVSI), cell type, tumor grade, lymph node metastases (LNM), parametrial invasion, surgical margin involvement, and pattern of adjuvant therapy were analyzed using univariate and multivariate methods to define those variables that best predicted RFS.
RESULTS: Outer 1/3 invasion, LVSI, and LNM were identified as independent poor prognostic factors, which were used to define three prognostic groups: patients (n = 104) with good prognoses (LVSI (-) and LNM (-)), patients (n = 46) with intermediate prognoses (either LVSI (+) without outer 1/3 invasion or LNM (+) without LVSI), and patients (n = 47) with poor prognoses (LVSI (+) patients with outer 1/3 invasion). The estimated 3-year RFS for patients with LVSI and deeply invasive tumors regardless of nodal status and/or nodal metastases receiving adjuvant CT + RT was significantly greater than that for patients who received only adjuvant radiotherapy (80% vs. 49%, P = 0.048 in the group of patients with LVSI and deeply invasive tumors with positive nodes and without positive nodes; 87% vs. 36%, P = 0.013 in the group of patients with LVSI and deeply invasive tumors with positive nodes only).
CONCLUSIONS: The multivariate analysis and prognostic grouping system maximally separated patients with early-stage invasive cervical carcinoma into groups with good, intermediate, or poor prognoses, with 3-year RFSs of 90%, 82%, 67%; and 5-year RFSs of 89%, 69%, 43%, respectively. CT + RT played a role in improving RFS among patients with LVSI and deeply invasive tumors and poor prognoses.

Entities:  

Mesh:

Year:  2004        PMID: 15099962     DOI: 10.1016/j.ygyno.2004.01.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  45 in total

1.  Angiopoietin-1 is associated with a decreased risk of lymph node metastasis in early stage cervical cancer.

Authors:  E Cai; Dongyun Yang; Yifan Zhang; Jing Cai; Si Sun; Ping Yang; Yuhui Huang; Qing Han; Zhoufang Xiong; Shaohai Wang
Journal:  Histol Histopathol       Date:  2020-06-17       Impact factor: 2.303

2.  [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology].

Authors:  L-C Horn; M W Beckmann; M Follmann; M C Koch; P Mallmann; S Marnitz; D Schmidt
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

Review 3.  Usefulness, methods and rationale of lymph nodes HPV-DNA investigation in estimating risk of early stage cervical cancer recurrence: a systematic literature review.

Authors:  Marco Noventa; Emanuele Ancona; Erich Cosmi; Carlo Saccardi; Pietro Litta; Donato D'Antona; Giovanni Battista Nardelli; Salvatore Gizzo
Journal:  Clin Exp Metastasis       Date:  2014-07-20       Impact factor: 5.150

4.  A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors.

Authors:  Pei Shu; Yali Shen; Yaqin Zhao; Feng Xu; Meng Qiu; Qiu Li; Hongfeng Gou; Dan Cao; Yu Yang; Jiyan Liu; Cheng Yi; Zhengyin Liao; Deyun Luo; Feng Bi; Xin Wang; Zhiping Li
Journal:  Med Oncol       Date:  2015-10-03       Impact factor: 3.064

5.  Adjuvant chemoradiation after laparoscopically assisted vaginal radical hysterectomy (LARVH) in patients with cervical cancer: oncologic outcome and morbidity.

Authors:  Arne Gruen; Thabea Musik; Christhardt Köhler; Jürgen Füller; Thomas Wendt; Carmen Stromberger; Volker Budach; Achim Schneider; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

6.  Significance of heparanase in metastatic lymph nodes of cervical squamous cell cancer.

Authors:  Bin Hu; Qing Wang; Yingying Shi; Shufang Lu; Hongjie Qu; Lu Wang; Jinquan Cui
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

Review 7.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Daniela D Rosa; Lídia R F Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

8.  Perineural invasion in early-stage cervical cancer and its relevance following surgery.

Authors:  Yi Zhu; Guonan Zhang; Yan Yang; Ling Cui; Shijun Jia; Yu Shi; Shuiqin Song; Shiqiang Xu
Journal:  Oncol Lett       Date:  2018-02-26       Impact factor: 2.967

9.  Sentinel node detection with (99m)Tc phytate alone is satisfactory for cervical cancer patients undergoing radical hysterectomy and pelvic lymphadenectomy.

Authors:  Shinji Ogawa; Hiroaki Kobayashi; Satoshi Amada; Hideaki Yahata; Kenzo Sonoda; Koichiro Abe; Shingo Baba; Masayuki Sasaki; Tsunehisa Kaku; Norio Wake
Journal:  Int J Clin Oncol       Date:  2010-01-21       Impact factor: 3.402

10.  Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.

Authors:  E R Nijhuis; H W Nijman; K A Oien; A Bell; K A ten Hoor; N Reesink-Peters; H M Boezen; H Hollema; A G J van der Zee
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.